Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2019.00060
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy

Frontiers in Pharmacology
Pharmacology
2020English

Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza a Virus Replication

Assay and Drug Development Technologies
Drug DiscoveryMolecular Medicine
2015English

Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses

Angewandte Chemie - International Edition
CatalysisChemistry
2016English

Repurposing FDA-approved Drugs as Therapeutics to Treat Rift Valley Fever Virus Infection

Frontiers in Microbiology
Microbiology
2015English

Gene Expression Signatures as a Therapeutic Target for Severe H7N9 Influenza – What Do We Know So Far?

Expert Opinion on Therapeutic Targets
Molecular MedicineDrug DiscoveryClinical BiochemistryPharmacology
2015English

New Drug Candidates for Treatment of Atypical Meningiomas: An Integrated Approach Using Gene Expression Signatures for Drug Repurposing

PLoS ONE
Multidisciplinary
2018English

Possible Repurposing of Seasonal Influenza Vaccine for Prevention of Zika Virus Infection

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2016English

Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies

Drugs
Pharmacology
2014English

Furan-Carboxamide Derivatives as Novel Inhibitors of Lethal H5N1 Influenza a Viruses

RSC Advances
ChemistryChemical Engineering
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy